| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H16ClN3O |
| Molar mass | 277.75 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
ELB-139 (LS-191,811) is ananxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects tobenzodiazepine drugs, but is structurally distinct and so is classed as anonbenzodiazepine anxiolytic.[1][2]
ELB-139 is a subtype-selectivepartial agonist atGABAA receptors, with highestaffinity for the α3 subtype, but highestefficacy at α1 and α2.[3] It has primarilyanxiolytic andanticonvulsant effects, but produces littlesedative effects orataxia,[4] and has also been demonstrated in rats to increaseserotonin levels in thestriatum andprefrontal cortex, without affectingdopamine levels.[5] It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans[6] The sponsor elbion AG registered a clinical trial inClinicalTrials.govfor the treatment of anxiety associated with panic disorder but the results have not been reported.[7] It was developed by Arzneimittelwerk Dresden in the 1990s.[8]
This article about ananxiolytic is astub. You can help Wikipedia byexpanding it. |